Recently, the domain of diabetes treatment has witnessed a wave of innovation with the development of novel therapies targeting GLP-1 receptors. Among these groundbreaking advancements are retatrutide and trizepatide, two innovative medications that exhibit significant advantages over conventional therapies. Retatrutide, a once-weekly treatment, d